Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 5, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare Conference. Toloue will speak alongside Chief Financial Officer Vandana Sriram in a fireside chat presentation on Wednesday, June 12, 2024, at 2:40 p.m. EST. The session will be made available to attendees and the general public via webcast.
馬薩諸塞州比勒利卡 - (商業線) - 2024年6月5日 - Quanterix公司（納斯達克：QTRX）是一家通過超敏生物標記物檢測推動科學發現的公司。今天宣佈首席執行官Masoud Toloue將於2024年6月12日星期三下午2:40在高盛第45屆全球醫療保健大會上與首席財務官Vandana Sriram一起進行點燃談話演示。此次會議將通過網絡直播向與會者和公衆開放。
Webcast Information
網絡研討會信息
To access the live webcast of Quanterix's fireside chat presentation at the conference, please visit this link.
若要訪問會議上Quanterix點燃談話演示的直播，請訪問此鏈接.
Replays of the presentation will be available for a limited period following the conference. The presentation will also be made available through the Investor Relations section of the company's website.
會後有限期間內將提供演示的重播。該演示也將通過公司網站的投資者關係部分提供。
To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa technology, visit www.quanterix.com/simoa-technology.
要了解更多有關Quanterix的信息，請訪問www.quanterix.com/company要了解有關Quanterix Simoa技術的更多信息，請訪問www.quanterix.com/simoa-technology.
About Quanterix
關於Quanterix
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
從探索到診斷，Quanterix的超敏生物標記物檢測通過其無與倫比的靈敏度和適應性推動了突破。該公司的Simoa技術提供了血液、血清或血漿中更早期生物標誌物檢測的黃金標準，能夠量化遠低於檢測限（LoQ）的蛋白質。其行業領先的精密儀器、數字免疫測定技術和CLIA認證的Accelerator實驗室支持了神經學、腫瘤學、免疫學、心臟病學和傳染病領域的疾病認知和管理的研究。Quanterix已成爲科學界近20年的可靠合作伙伴，支持在2900多個同行評審期刊上發表的研究。在位於馬薩諸塞州比勒利卡的該公司網站上查找有關該公司的其他信息https://www.quanterix.com或關注我們的推特和頁面。LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240605682576/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240605682576/en/
Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
媒體聯繫人：
PAN通訊
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
投資者關係聯繫方式：
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com
Source: Quanterix Corporation
來源：quanterix公司